medical patient
An AI generated image depicting a phone displaying biometric health data. Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

BlinkLab (ASX:BB1) has teamed up with a college in Maine, USA to assess its capacity to leverage its tech in the field of functional neurological disorder (FND) diagnosis.

The FND label is not itself one condition but refers to a group of common neurological disorders which broadly affect movement and cognition.

The news comes only one day after the company revealed its commencement of a two year trial with a Dutch institution to gear its autism diagnosis tech towards diagnosing dementia.

BlinkLab’s overall premise is that in-phone software can be used to track eye movements of users, and that those eye movements can reliably predict anomalous behaviours associated with autism as concluded in peer reviewed journals.

Management on Wednesday informed shareholders the company’s focus would remain on autism but that the emerging field posed multiple points of inquiry worth pursuing for BlinkLab – quite literally, if they come off and there’s commercial opportunity.

The ability to conduct tests using only a mobile phone is also a benefit for the company, given that costs associated with such a trial are thus greatly reduced.

Patients with FND in Maine, New York, New Jersey and “other locations” will participate. It could run for up to 3 years, with Maine-based Bates College’s Dr. Olivia Kim leading the study. BlinkLab is hopeful it can get up to 500 patients.

“The app’s capacity to collect high-quality data in a location of the participants’ choosing will be key for reaching patients with Functional Neurological Disorder (FND),” Bates College Assistant Professor Dr. Olivia Kim said.

This will let us overcome logistical barriers that can make joining conventional, in-laboratory studies burdensome.”

Per its deal in the Netherlands on Wednesday, BlinkLab also stands to claim patent rights to any IP produced as part of the trial.

BB1 last traded at 28cps.

BB1 by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Sentiment getting better with finish over 7,900pts

Good afternoon and welcome to HotCopper’s Market Close for Thursday, I’m Jonathon Davidson.It was another better-looking…
HotCopper Podcast Graphic which reads Episode 005 with copy about the markets being in the red.

Listen: HotCopper Podcast 005 – It’s red, red, red everywhere we look this week

In this HotCopper podcast episode, we talk through WA Labor's third-term victory and the mega-sized ASX…
The Market Online Video

ASX Market Open: Fed’s ‘two cut’ call shoots more hope into Week 12 rally | March 20, 2025

Futures say Australian shares will rise as much as 0.8% this Thursday morning, with a big jump at open likely to push th…
HotCopper Podcast Graphic which reads Episode 006 with copy about the markets being in the red.

Listen: HotCopper Podcast 006 – What comes first, the bear market or the election?

Welcome to this week’s HotCopper Wire, our market watch podcast!